Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”
-
Published:2023-06-05
Issue:
Volume:10
Page:82-86
-
ISSN:2465-2628
-
Container-title:AboutOpen
-
language:
-
Short-container-title:AboutOpen
Author:
Secchi OttavioORCID,
Franchi AndreaORCID,
Lunello ArmandoORCID
Publisher
Aboutscience Srl
Subject
Materials Chemistry
Reference12 articles.
1. Ravasio R, Viti R, Roscini SA. Costo per responder di vedolizumab e ustekinumab nel trattamento della malattia di Crohn in pazienti che hanno fallito una precedente terapia con un antagonista del TNF-α in Italia. AboutOpen | 2023; 10: 13-21. https://doi.org/10.33393/ao.2023.2515
2. Onali S, Pugliese D, Caprioli FA, et al; IG-IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn’s Disease Patients’ Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022;117(8):1279-1287. https://doi.org/10.14309/ajg.0000000000001773 PMID:35467558
3. Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948-957. https://doi.org/10.1111/apt.15706 PMID:32249966
4. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52(8):1341-1352. https://doi.org/10.1111/apt.16057 PMID:32955122
5. Ibing S, Cho JH, Böttinger EP, Ungaro RC. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis. Clin Gastroenterol Hepatol. 2023 Feb 12:S1542-3565(23)00105. https://doi.org/10.1016/j.cgh.2023.01.038 PMID: 36787837